Sailong Pharmaceutical Group Co., Ltd.

Total Valuation

Sailong Pharmaceutical Group Co., Ltd. carries a market capitalization of 61.60M, placing it among publicly traded companies globally. Its enterprise value stands at 2.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Sailong Pharmaceutical Group Co., Ltd. currently has 176.00M shares outstanding.

Valuation Ratios

Sailong Pharmaceutical Group Co., Ltd. trades at a trailing price-to-earnings ratio of 311.39. The price-to-sales ratio is 8.28, and the price-to-book ratio stands at 11.32.

Enterprise Valuation

On an enterprise value basis, Sailong Pharmaceutical Group Co., Ltd. trades at an EV/EBITDA multiple of 7.01 and an EV/FCF ratio of 57.09. The EV/Sales ratio of 8.91 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 7.01 provides insight into valuation relative to core operating earnings.

Financial Position

Sailong Pharmaceutical Group Co., Ltd. maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 33.09, indicating elevated leverage, while an interest coverage ratio of -2.86 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Sailong Pharmaceutical Group Co., Ltd.'s stock has declined approximately -97.05635% over the past 52 weeks. The 50-day moving average sits at 7.40, while the 200-day moving average is 11.53.

Income Statement

Over the trailing twelve months, Sailong Pharmaceutical Group Co., Ltd. generated 243.21M in revenue and converted that into -49.74M in net income, yielding earnings per share of -0.28. EBITDA reached -21.70M, while operating income came in at -21.70M.

Balance Sheet

Sailong Pharmaceutical Group Co., Ltd. holds 6.88M in cash and equivalents against 160.64M in total debt, resulting in a net debt position of 124.89M. Total book value stands at 177.90M, with working capital of -32.21M providing operational flexibility.

Cash Flow

After subtracting -30.43M in capital expenditures, free cash flow totaled -30.43M - equivalent to -0.17 per share.

Margins

Sailong Pharmaceutical Group Co., Ltd. operates with a gross margin of 28.99, reflecting its pricing power and cost economics. The operating margin of -8.92 and net profit margin of -20.45 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -11.90 indicates the proportion of earnings distributed to shareholders.

Stock Splits

Sailong Pharmaceutical Group Co., Ltd.'s most recent stock split took place on July 16, 2020 with a 10:11 split ratio.

Scores

Sailong Pharmaceutical Group Co., Ltd. posts an Altman Z-Score of 4.66, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.